The effects of nevirapine, indinavir, and lamivudine in combination were studied among 22 human immunodeficiency virus (HIV) -infected patients with CD4 cell counts £50/mm 3 , whose options for antiretroviral therapy were limited by clinical or laboratory failure or toxicity with previous regimens. Median plasma HIV RNA was 5.16 log 10 copies/mL at baseline, decreasing by a median of 3.12 log 10 copies/mL at 24 weeks. Median baseline CD4 cell count was 30/mm 3 , increasing by a median of 95/mm 3 at week 24. Adverse reactions led to drug discontinuation in 4 cases. Steadystate pharmacokinetic analysis in 17 patients was consistent with an interaction between nevirapine and indinavir. Nevirapine plasma levels were within the expected range, while indinavir levels were lower than expected. Despite this interaction, the combination of nevirapine, indinavir, and lamivudine was safe and well-tolerated and had substantial antiviral and immunologic effects lasting for the 24-week study.
Combination antiretroviral therapy has been clearly shown concerning the effect of nevirapine on the pharmacokinetics of currently available protease inhibitors. As expected, nevirapine to be superior to monotherapy [1 -3] . More recently, tripledrug combinations including two nucleoside analogues plus was found to reduce the area under the curve (AUC) for indinavir, ritonavir, and saquinavir by Ç10% -30% when adminisa nonnucleoside reverse transcriptase inhibitor or a protease inhibitor have demonstrated superiority to double-nucleoside tered in combination [13, 14] . However, the clinical and virologic implications of this interaction have not been fully therapy in terms of surrogate marker effect and clinical outcome [4 -7] . On the basis of these results, triple-drug combinacharacterized. Therefore, we conducted a 24-week pilot study to assess the tion therapy is widely recommended for the treatment of human immunodeficiency virus (HIV) infection [8 -11] .
safety, antiviral and immunologic effects, and pharmacokinetics of nevirapine, indinavir, and lamivudine administered in Concomitant use of drugs, however, increases the chance of pharmacokinetic interactions. With the increasing use of protecombination among patients with advanced HIV disease who have had failure of combination nucleoside therapy. ase inhibitors and nonnucleoside reverse transcriptase inhibitors, concern has arisen regarding possible pharmacokinetic interactions between them [12 -14] . Nevirapine is a hepatic Methods enzymatic inducer and as such would be expected to decrease the effective serum concentrations of protease inhibitors [15] .
Patients. HIV-infected patients with CD4 cell counts £50/
Only recently has preliminary information become available mm 3 were eligible if they had demonstrated intolerance, toxicity, or disease progression with nucleoside analogue-based antiretroviral therapy. Eligible patients had no prior exposure to nevirapine or indinavir. Prior use of lamivudine was allowed.
Study design. This was a prospective, open-label study con- done four times on a single day. Patients were requested to take their usual oral doses of nevirapine at 8:00 P.M. and indinavir at 11:00 P.M. the night before testing, while they continued to take lamivudine on a regular schedule. The following day, a sample was drawn for trough nevirapine and indinavir levels at 7:00 A.M. 200 mg twice daily thereafter. Indinavir was given at 800 mg every
Morning doses of indinavir and nevirapine were taken immediately 8 h on an empty stomach. Lamivudine was given at 150 mg twice thereafter, and a sample was obtained for peak nevirapine and daily. Concurrent use of other antiretroviral therapies was not indinavir levels at 8:00 A.M. A second trough indinavir level was allowed. No washout period was required before starting study therapy.
drawn immediately prior to the 3:00 P.M. dose, and a second peak indinavir level was obtained at 4:00 P.M. Patients continued to take by each patient, was defined as 1 0 NAUC (normalized AUC) [17, 18] . A person with no change from the baseline HIV RNA their usual concomitant medications on the sampling day. Plasma was separated and frozen within 1 h of drawing and stored at value over the 24-week observation period would have a value of 070ЊC for batch testing. 0, while a person whose plasma HIV RNA was reduced to the Plasma samples were analyzed for nevirapine concentrations at quantitation limit of the Ultra Direct assay very quickly would have Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT) by use of a value close to 1. A negative value would result from increases in a validated high-performance liquid chromatographic assay with virus load relative to baseline, if the duration and size of the UV detection (wavelength Å 280 nm). Standard curves for the increases were large enough to counteract any decreases. analytical method covered the range of 25-10,000 ng/mL. The
Results for drug levels are reported as means { SDs. The relalimit of assay quantitation was 25 ng/mL. Quality control samples tionships between peak and trough levels of nevirapine and indianalyzed with each analytical run had coefficients of variation for navir and patients' virologic response to therapy, as measured by precision and accuracy of õ15%. Plasma samples were analyzed 1 0 NAUC, were summarized with scatter plots and Spearman's for indinavir concentrations at BAS Analytics (West Lafayette, correlation coefficients. For indinavir, for which two values for IN) by a proprietary validated high-performance liquid chromatopeak and trough were available for each patient, the correlation graphic assay with a limit of assay quantitation of 12 ng/mL.
was examined for 1 0 NAUC and absolute peak or trough levels Statistics. Median CD4 cell counts and plasma HIV RNA mea-(i.e., the higher of the two peaks and the lower of the two troughs). surements were calculated at baseline for the entire group and for Lowess (locally weighted scatter plot smoother) curves were drawn the subset of patients included in the pharmacokinetic analyses.
on the plots to summarize the relationships of pairs of variables. At every follow-up visit, the change shown by each person from
The lowess curve, which is akin to a moving average, was chosen his baseline CD4 cell count and plasma HIV RNA level was calcuinstead of fitting a straight line to the data, since the relationships lated. The median of these changes at each time point is expressed were nonlinear [19] . as ''median change.'' The proportions of patients with plasma HIV RNA measurements õ500 copies/mL and õ20 copies/mL were also tabulated at each follow-up visit. In cases in which
Results
Amplicor HIV-1 test results were õ500 copies/mL, Ultra Direct
Patients. A total of 22 patients were enrolled, and 17 were results were used in their place. Ultra Direct results below the available for the pharmacokinetic study (table 1). Only 1 patient quantitation limit of this assay (20 copies/mL) were set to 20.
had previously used a protease inhibitor (ritonavir), and the The cumulative antiviral treatment effect over 24 weeks, or the proportion of potential improvement in plasma HIV RNA achieved drug had been discontinued after 14 weeks because of dizzi- Figure 2 . Proportion of patients with plasma HIV RNA below quantitation limit of standard (500 or 2.7 log 10 copies/mL; solid line) and Ultra Direct (20 or 1.3 log 10 copies/mL; dashed line) assays, versus time receiving study drug.
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04-16-98 09:24:16 jinfa UC: J Infect ness, hot flashes, fatigue, and diarrhea. Two patients had preImmunologic response. CD4 cell counts increased substantially over the 24-week study period (figure 1). The median viously received loviride (an experimental nonnucleoside reverse transcriptase inhibitor) as part of their participation in CD4 cell count was 30/mm 3 at baseline. The median change in CD4 cell count was /30 cells/mm 3 at week 4 and /95 cells/ the CAESAR trial [3] . All patients except 3 had prior experience with lamivudine. mm 3 at week 24. Changes in CD4 cell counts for the 17 patients eligible for the pharmacokinetic study followed a similar patThere were no withdrawals attributable to clinical progression or laboratory treatment failure (i.e., increasing plasma vitern (data not shown).
Pharmacokinetics. Observed nevirapine plasma levels varrus load) during the study period. Three patients withdrew for personal reasons, unrelated to toxicity or lack of efficacy.
ied little between patients and within individuals during the course of the day and were not affected by coadministration Safety. No unexpected clinical or laboratory adverse events occurred during the study.
of indinavir (figure 3). Nevirapine peak was 21.6 { 8.3 mM and nevirapine trough was 18.3 { 5.7 mM. These values did No serious (grade §3) clinical adverse events to the study medications were encountered during the study. Adverse events not differ significantly from published data for nevirapine monotherapy [20] (P Å .074 and .25, respectively). of moderate severity (grade 2) led to the discontinuation of nevirapine or indinavir in 4 patients. In 2 of these cases, the In contrast, observed indinavir plasma levels varied widely between patients and within individuals during the course of events (nausea/vomiting and rash) were attributed to nevirapine, and in the other 2 cases the events (urinary frequency/ the day and appeared to be reduced substantially in the presence of nevirapine (figure 4). Indinavir peak levels were 6401 { nocturia and nausea/vomiting) were attributed to indinavir. No cases of nephrolithiasis were observed. A single new AIDS-4416 nM for the morning dose and 3285 { 3373 nM for the afternoon dose. These represent 51% and 26%, respectively, defining opportunistic infection occurred during the 24-week follow-up period: a case of Pneumocystis carinii pneumonia of the published levels for indinavir when given alone [21] (P õ .001 and õ .001, respectively). The observed indinavir diagnosed during week 3 of the study in a patient with a previous AIDS diagnosis. trough levels were 109 { 66.6 nM in the morning and 109 { 56.3 nM in the afternoon, representing 43% of published levels Two grade §3 laboratory toxicities occurred during the study. One patient developed hyperbilirubinemia (maximum level, 65 for indinavir monotherapy [21] (P Å .0075 and .0068, respectively). mmol/L Å 3.8 mg/dL), which resolved after a 4-day interruption of indinavir; therapy was resumed without recurrence. Another
Correlation of pharmacokinetics and virologic responses. The cumulative antiviral effect, represented by 1 0 NAUC for patient developed worsening of preexisting neutropenia (decreasing from 900 at baseline to 300 cells/mm 3 at week 16 during HIV RNA over 24 weeks, did not show a statistically significant correlation with nevirapine peak (Spearman's correlation coeffitherapy). Thereafter, lamivudine was replaced by stavudine, while indinavir and nevirapine were continued. Pharmacokinetic sampling was done for this patient before the change in therapy. No cases of chemical hepatitis were observed.
Virologic response. Plasma virus load decreased rapidly from baseline, and this decrease was maintained for the 24-week study period (figure 1). The median plasma virus load was 5.16 log 10 at baseline. Median changes in plasma virus load were 02.42 log 10 copies/mL at 4 weeks, 03.04 log 10 copies/mL at 12 weeks, and 03.12 log 10 copies/mL at 24 weeks. The plasma virus load changes in the pharmacokinetic subgroup followed a similar pattern (data not shown).
Virus load was suppressed to below the limits of quantitation of the HIV RNA assays in a substantial proportion of patients (figure 2). At week 24, 73% of patients (11/15) had plasma virus load õ500 copies/mL, and 40% (6/15) of patients had plasma virus load õ20 copies/mL.
The patient with prior ritonavir experience and 1 of the patients with prior loviride experience showed good virologic responses to the study combination, achieving plasma virus loads of 33 and cient Å .27, P Å .29), with nevirapine trough (correlation coeffiincorporated steady-state peak and trough drug level determinations in an attempt to correlate pharmacokinetic variables with cient Å .38, P Å .13), nor with absolute indinavir peak levels (correlation coefficient Å .42, P Å .10). However, a statistically clinical laboratory changes and particularly with virologic effect. We elected to retain lamivudine within the therapeutic significant correlation was found between the 24-week cumulative antiviral effect and the absolute indinavir trough levels (correlation regimen despite the fact that a majority of the study participants had previously demonstrated evidence of treatment failure with coefficient Å .53, P Å .03) (figure 5).
this agent and likely carried drug-resistant virus isolates. Given the very favorable safety profile of lamivudine, we felt that Discussion retaining it would not compromise the safety of the combination regimen [3, 22 -25] . Furthermore, there has been some The results of this pilot study demonstrate that standard doses of nevirapine, indinavir, and lamivudine are generally wellevidence suggesting that HIV strains resistant to lamivudine may have decreased fitness [26] . In addition, in vitro evidence tolerated and can lead to substantial reductions in plasma virus load and increases in CD4 cell count. This effect was demonhas been generated suggesting that there may be a synergistic interaction between lamivudine and nevirapine [27] . strated among patients with advanced HIV disease who previously had either disease progression or virologic failure while
We found that nevirapine, indinavir, and lamivudine given in combination had very substantial antiviral and immunologic receiving nucleoside analogue -based combination therapy, often including lamivudine. In addition, our data support the effects. Plasma virus load decreased rapidly on initiation of therapy, leading to a median reduction in plasma HIV RNA existence of a pharmacokinetic interaction between nevirapine and indinavir, characterized by indinavir peak and trough conof ú3 log 10 copies/mL, which remained for the 24 weeks of the study. This was associated with a median increase in CD4 centrations being significantly lower than expected compared with historical controls; however, this interaction does not precell count of 95 cells/mm 3 , which remained at 24 weeks. The magnitude of these immunologic and virologic responses is clude a substantial immunologic and virologic response.
The management of HIV-infected persons continues to particularly encouraging when considering the very advanced stage and extensive prior antiretroviral therapy use of our study evolve at a rapid pace. Now that the single-drug therapy strategy is abandoned, multiple-drug combinations are currently group. Previous exposure to a nonnucleoside reverse transcriptase inhibitor (2 patients), a protease inhibitor (1 patient), used with the aim of suppressing viral replication as much as possible for as long as possible [6 -11] . Patients who started or lamivudine (19 patients) did not preclude a favorable response to the combination. Furthermore, unexpected adverse treatment before these guidelines were developed often face difficult challenges when making therapeutic decisions. It is effects were not encountered within this group of patients. Our pharmacokinetic data support the existence of an interacwithin this context that in the late spring of 1996, having gained access to two new promising antiretroviral agents, nevirapine tion between nevirapine and indinavir, as recently reported [13] . This interaction is characterized by plasma concentrations and indinavir, we offered this combination to persons who had exhausted conventional treatment approaches. Because of the of indinavir (both peak and trough levels) being significantly lower than expected in comparison to historical controls. Limpotential for drug interactions, we did so under close clinical and laboratory monitoring within this pilot study. Further, we ited pharmacokinetic sampling in our study precludes a precise / 9d46$$ju25 04-16-98 09:24:16 jinfa UC: J Infect estimation of the magnitude of the interaction. However, our rameters and antiviral effect. When the cumulative antiviral effect (represented by 1 0 NAUC for HIV RNA over 24 results are consistent with those encountered in the context of pharmacokinetic interaction studies in which coadministration weeks) was plotted against pharmacokinetic parameters for nevirapine and indinavir, a statistically significant correlaof nevirapine and indinavir led to an Ç30% reduction in indinavir AUC [13] .
tion was present only for the absolute indinavir trough (figure 5). The higher the absolute trough level of indinavir for an A substantial degree of variability in the peak and trough concentrations of indinavir is illustrated by our data. This findindividual within the study group, the greater tended to be the cumulative antiviral effect achieved by that individual ing is consistent with available data from intensive pharmacokinetic studies [21] . Comparing the pharmacokinetic parameters over the 24-week study period. The results of this exploratory analysis suggest that increasing indinavir dose in some encountered for our patients with those reported for patients receiving indinavir monotherapy, it is evident that although patients may optimize antiviral effect when given in combination with nevirapine. This issue needs to be further evaluindinavir levels are significantly lower in the presence of nevirapine, there is a substantial degree of overlap with indinavir ated in prospective clinical trials. In summary, our results demonstrate that standard doses of levels achieved without nevirapine. Taken together, these data suggest that a strategy of adjusting indinavir dose based on nevirapine, indinavir, and lamivudine given in combination are generally safe and well-tolerated and have substantial antiviral measurements of trough serum concentrations should be further evaluated, whether or not nevirapine is included in the regimen.
and immunologic effects among advanced, heavily pretreated HIV-infected patients. Our data also support the existence of a Our data also illustrate a relatively small variation between the peak and trough concentrations for nevirapine. These results pharmacokinetic interaction between nevirapine and indinavir.
The clinical implication of this interaction and the role of dosare consistent with previous reports [20] and lead us to speculate that nevirapine could be effectively used in a once-daily age adjustments for indinavir merit further study. regimen, in combination with other antiretroviral agents. Clini-
